April 14, 2016 News by admin Array of Multiple Sclerosis Trial Data to Be Presented by Biogen at 2016 AAN Meeting A rangeĀ of new multiple sclerosis (MS) data from Biogen will be revealedĀ atĀ the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on April 15ā21. Presentations will include studies on TecfideraĀ (dimethyl fumarate),Ā one of the most frequently usedĀ oral MS treatments worldwide, as well as several other…
April 7, 2016 News by Patricia Silva, PhD Doctors Study Possible Link Between Dimethyl Fumarate (Tecfidera) and Shingles A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with dimethyl fumarate (Tecfidera) has raised questions of whether the drug reactivatesĀ the varicella-zoster virus. The study,Ā “Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate,“Ā was published in…
April 1, 2016 News by Patricia Silva, PhD MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells Editor’s note: The term B-cells is, in fact, a collective term for a group of cells having rather different properties. Some B-cells cells play a role in fighting invading pathogens or flawed cells, and can be wrongfully activated to target normal cells in autoimmune diseases. Regulatory B-cells (Bregs), instead act…
January 29, 2016 News by Charles Moore Multiple Sclerosis Patient and ‘Sopranos’ Actress Takes MS Struggle Public Millions of television viewers who watchedĀ the popularĀ HBO mob drama series “The Sopranos”Ā saw actress Jamie Lynn Sigler grow from a teen into a young woman as Meadow Soprano, theĀ independent-minded daughter of mafia boss Tony Soprano, played by the late James Gandolfini. This week, Sigler revealed she has been battling multiple…
January 27, 2016 News by Patricia Silva, PhD Tecfidera Seen to Alter Anti-Inflammatory Profile in Immune Cells Delayed-release dimethyl fumarate (Tecfidera) was recently approved for patients with relapsing-remitting multiple sclerosis (RRMS), although the mechanisms by which the drug exerts its action wereĀ not fully understood. A new study from the University Hospital MĆ¼nster, Germany, shows that dimethyl fumarate alters the balance between subpopulations of T-cells to promote…
December 18, 2015 News by Patricia Silva, PhD New MS Drug Therapy Based on Monomethyl Fumarate Moving Along in Testing Alkermes plc, a biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, announced that it has successfully met its 2015 goals for their product and late-stage pipeline drug portfolio, including ALKS 8700, a monomethyl fumarate (MMF) drug candidate for the treatment of multiple sclerosis…
December 14, 2015 News by Patricia Silva, PhD 2 New Treatments for Relapsing-Remitting MS Now Available in New Zealand The Multiple Sclerosis Society of New Zealand (MSNZ)Ā announced thatĀ PHARMAC has agreed with its requestĀ toĀ finance two novel first-in-line therapies for relapsing-remitting forms of multiple sclerosis (MS), making them accessible to patients there. PHARMAC recently agreed to fund theĀ two treatments, teriflunomide (Aubagio), supplied by Sanofi-Aventis NZ, and dimethyl fumarate (Tecfidera),…
October 22, 2015 News by Patricia Silva, PhD Biogen’s Investment in Multiple Sclerosis Therapies Reinforced in Company Restructuring Advancing key medicinal treatments likeĀ TECFIDERA (dimethyl fumarate), the most prescribed oral treatment for multiple sclerosis (MS), is a key focus of a company-wide restructuring recently announced byĀ Biogen, Inc.Ā TECFIDERA has been shown to reduce relapse rates, slow disability progression and the number of brain lesions in patients with relapsing forms…
October 9, 2015 News by Patricia Silva, PhD EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015 A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled āMS developments: transitioning evidence into clinical practiceā presentedĀ by the companyĀ this morning at the 31st Congress of the European Committee for Treatment and…
October 8, 2015 News by Patricia Silva, PhD Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015 Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…